Unknown

Dataset Information

0

Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma.


ABSTRACT: Background:Median overall survival is 12 to 15 months in patients with metastatic adrenal cortical carcinoma (ACC). Etoposide, doxorubicin, and cisplatin with or without the adrenolytic agent mitotane is considered the best first-line approach in this context, but has limited activity and no curative potential; additional salvage therapeutic options are needed. Methods:Fifteen total patients with recurrent/metastatic ACC were treated with single-agent multikinase inhibitors (MKI) (n = 8), single-agent PD-1 inhibition (n = 8), or cytotoxic chemotherapy plus PD-1 inhibition (n = 4) at our institution as later-line systemic therapies in efforts to palliate disease and attempt to achieve a therapeutic response when not otherwise possible using standard approaches. Results:Two of 8 patients (25%) treated with single-agent MKI achieved a partial response (PR), including 1 PR lasting 23.5 months. Another 3 patients (38%) had stable disease (SD); median progression-free survival (PFS) with single-agent MKI was 6.4 months (95% confidence interval [CI] 0.8-not reached). On the other hand, 2 of 12 patients (17%) treated with PD-1 inhibitors (either alone or in combination with cytotoxic chemotherapy) attained SD or better, with 1 patient (8%) achieving a PR; median PFS was 1.4 months (95% CI 0.6-2.7). Conclusions:Our single-institution experience suggests that select ACC patients respond to late-line MKI or checkpoint inhibition despite resistance to cytotoxic agents. These treatments may be attractive to ACC patients with limited other therapeutic options. The use of MKI and immunotherapy in ACC warrants prospective investigation emphasizing parallel correlative studies to identify biomarkers that predict for response.

SUBMITTER: Miller KC 

PROVIDER: S-EPMC7326479 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma.

Miller Kevin C KC   Chintakuntlawar Ashish V AV   Hilger Crystal C   Bancos Irina I   Morris John C JC   Ryder Mabel M   Smith Carin Y CY   Jenkins Sarah M SM   Bible Keith C KC  

Journal of the Endocrine Society 20200609 7


<h4>Background</h4>Median overall survival is 12 to 15 months in patients with metastatic adrenal cortical carcinoma (ACC). Etoposide, doxorubicin, and cisplatin with or without the adrenolytic agent mitotane is considered the best first-line approach in this context, but has limited activity and no curative potential; additional salvage therapeutic options are needed.<h4>Methods</h4>Fifteen total patients with recurrent/metastatic ACC were treated with single-agent multikinase inhibitors (MKI)  ...[more]

Similar Datasets

| S-EPMC9939209 | biostudies-literature
| S-EPMC4260520 | biostudies-literature
| S-EPMC8700734 | biostudies-literature
| S-EPMC9806143 | biostudies-literature
| S-EPMC5025874 | biostudies-literature
| S-EPMC6693704 | biostudies-literature
2021-09-07 | PXD027404 | Pride
| S-EPMC7068224 | biostudies-literature
| S-EPMC8125389 | biostudies-literature
| S-EPMC8241782 | biostudies-literature